Results 131 to 140 of about 4,842,335 (379)

Immobilized Enzymes for ABO‐Independent Blood Cell Transfusions

open access: yesChemBioChem, EarlyView.
A method is developed to generate universal red blood cells and platelets using suitable glycosidases immobilized to polymethacrylate microparticles. This approach allows the efficient removal of the enzymes converting the A and B antigens before transfusion to avoid immune reactions and illustrates a promising method to counteract the demand for blood
Christina Möller   +11 more
wiley   +1 more source

Guideline on the investigation and management of acute transfusion reactions Prepared by the BCSH Blood Transfusion Task Force [PDF]

open access: bronze, 2012
Hazel Tinegate   +9 more
openalex   +1 more source

Human Protein Z as the Second Known Heme‐Binding Protein from the Endogenous Blood Coagulation Inhibitor System

open access: yesChemBioChem, EarlyView.
Protein Z is a vitamin K‐dependent anticoagulant with elusive molecular functions. Herein, it is shown that heme binds to protein Z and induces conformational changes. One histidine‐based heme‐binding motif is identified. High heme‐binding affinity and functional effects are demonstrated on protein level. These findings shed new light on the structural
Paula Lindemann, Marie‐T. Hopp
wiley   +1 more source

Clinical Practice Simulation for Blood Transfusion Reactions: An Interprofessional Approach [PDF]

open access: bronze, 2015
Justin R. Rhees   +6 more
openalex   +1 more source

Synthesis and In Vitro Activity of Hypofuran B and Analogs Against Plasmodium Falciparum and Trypanosoma Cruzi

open access: yesChemMedChem, EarlyView.
Hypofuran B, drynaran, and a series of analogs are obtined by crossed aldol condensation from furfural dereivatives. Compunds are tested for in vitro activity agaisnt Trypanosoma cruzi and Plasmodium falciparum. Best results are obtained Against P. falciparum, with IC50 values ranging from 5,35 to 10,35 µg mL−1.
Cristiane Aparecida Franco   +11 more
wiley   +1 more source

Population Pharmacokinetics and Exposure–Response Analyses of Momelotinib, Its Active Metabolite (M21), and Total Active Moiety in Myelofibrosis

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Momelotinib, a Janus kinase (JAK) 1/JAK2/activin A receptor type 1 inhibitor, is approved for the treatment of myelofibrosis with anemia. These analyses characterized the population pharmacokinetics of momelotinib and its active metabolite M21 following administration of the commercial tablet formulation in patients with myelofibrosis from phase II/III
Benjamin Rich   +5 more
wiley   +1 more source

Research progress of hyperhemolytic syndrome after transfusion

open access: yesZhongguo shuxue zazhi
Hemolytic transfusion reactions after transfusion include acute hemolytic transfusion reaction and delayed hemolytic transfusion reaction. However, clinically, it is observed that after transfusion, the hemoglobin (Hb) level not only fails to increase ...
HE Ziyi
doaj   +1 more source

Rh Negative Status and Isoimmunization Update: A Case-Based Approach to Care [PDF]

open access: yes, 2003
Prior to the 1970s and the advent of Rho (D) immune globulin (RIG) for Rh negative women, hemolytic disease of the newborn led to morbidity, long-term disabilities, and mortality.
Hanson, Lisa   +3 more
core   +1 more source

Home - About - Disclaimer - Privacy